You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 202317809
Dec 20234609
Jan 20243703
Feb 20243005
Mar 202436072
Apr 20243205
May 20242002
Jun 20241802
Jul 20242005
Aug 20241202
Sep 20241803
Oct 20242406
Nov 20241806
Dec 20241607
Jan 20252804
Feb 2025407
Mar 2025004
Apr 2025102
May 2025006
Jun 2025004
Total5380163